glp1versus

Bydureon BCise vs Zepbound

exenatide extended-release (GLP-1 receptor agonist) vs tirzepatide (Dual GIP and GLP-1 receptor agonist) — a complete side-by-side comparison.

AstraZenecaEli Lilly

Bydureon BCise weight loss

2.3%

Zepbound weight loss

22.5%

Bydureon BCise dosing

Once weekly

Zepbound dosing

Once weekly

Reviewed by Dr. Elena Vance, DOLast reviewed 14 sources cited

Quick Summary

Bydureon BCise (exenatide) and Zepbound (tirzepatide) are both incretin-based therapies. In clinical trials, Zepbound showed greater weight loss (22.5% vs 2.3%).

See the comparison table below for detailed side-by-side data.

Bydureon BCise vs Zepbound: Full Comparison

FeatureBydureon BCise(exenatide extended-release)Zepbound(tirzepatide)
Active Ingredientexenatidetirzepatide
Drug ClassGLP-1 receptor agonistDual GIP and GLP-1 receptor agonist
ManufacturerAstraZenecaEli Lilly
FDA Approved2012-01-272023-11-08
Approved Indications
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity (adjunct to diet and exercise)
  • Treatment of moderate-to-severe obstructive sleep apnea in adults with obesity (December 20, 2024)
Routesubcutaneous injectionsubcutaneous injection
FrequencyOnce weeklyOnce weekly
Starting Dose2 mg weekly2.5 mg weekly
Maintenance Dose2 mg weekly5 mg, 10 mg, or 15 mg weekly
Max Dose2 mg weekly15 mg weekly
Weight Loss (%)2.3%22.5%
A1C Reduction1.3%N/A (not indicated for diabetes)
Key TrialDURATION-1 (30 weeks)SURMOUNT-1 / SURMOUNT-5 (head-to-head vs semaglutide) (72 weeks)
List Price$800-$950/month$1,060-$1,176/month
With Insurance$25-$100/month (varies by plan)$25-$250/month (varies; weight-loss coverage is limited)
Savings CardLimited savings programs available$25/month (Lilly savings card, commercially insured)

Side Effects: Bydureon BCise vs Zepbound

Side EffectBydureon BCiseZepbound
Nausea11%24-33%
Diarrhea9%18-25%
Injection site nodule10-17%Not reported
Headache8%Not reported
Vomiting4%10-18%
Constipation6%13-17%
Pancreatitis (rare)<1%<1%
Abdominal painNot reported10-14%
DyspepsiaNot reported7-10%
Injection site reactionNot reported3-7%
Hair lossNot reported5-6%
Gallbladder eventsNot reported1.6%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Bydureon BCise vs OzempicZepbound vs OzempicBydureon BCise vs WegovyZepbound vs WegovyBydureon BCise vs MounjaroZepbound vs MounjaroBydureon BCise vs RybelsusZepbound vs Rybelsus

Frequently Asked Questions

Sources & References

FDA & Regulatory

  1. Bydureon BCise FDA Drugs@FDA approval record — FDA
  2. Zepbound FDA Drugs@FDA approval record — FDA

Clinical Trial Records

  1. DURATION-1 clinical trial record — ClinicalTrials.gov
  2. SURMOUNT-1 / SURMOUNT-5 (head-to-head vs semaglutide) clinical trial record — ClinicalTrials.gov

Peer-Reviewed Literature

  1. Drucker DJ et al. Exenatide once weekly versus twice daily for treatment of type 2 diabetes (DURATION-1). Lancet 2008;372:1240-1250 — The Lancet
  2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216 — New England Journal of Medicine
  3. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med 2024;391:1193-1205 — New England Journal of Medicine

Safety Communications

  1. FDA approves first medication for obstructive sleep apnea (Zepbound OSA indication, December 20, 2024) — FDA

Manufacturer Information

  1. Bydureon BCise patient website (AstraZeneca) — AstraZeneca
  2. Zepbound patient and healthcare provider website — Eli Lilly
  3. Lilly lowers price of Zepbound single-dose vials (December 1, 2025) — Eli Lilly Investor Relations
  4. SURMOUNT-5: Zepbound superior weight loss over Wegovy (May 11, 2025) — Eli Lilly Investor Relations

Reference Entries

  1. Exenatide entry on Wikipedia — Wikipedia
  2. Tirzepatide entry on Wikipedia — Wikipedia

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.